A proteomic platform to identify off-target proteins associated with therapeutic modalities that induce protein degradation or gene silencing

Novel modalities such as PROTAC and RNAi have the ability to inadvertently alter the abundance of endogenous proteins. Currently available in vitro secondary pharmacology assays, which evaluate off-target binding or activity of small molecules, do not fully assess the off-target effects of PROTAC an...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Xin, Zhang, Ye, Ward, Lucas D., Yan, Qinghong, Bohnuud, Tanggis, Hernandez, Rocio, Lao, Socheata, Yuan, Jing, Fan, Fan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8338952/
https://www.ncbi.nlm.nih.gov/pubmed/34349202
http://dx.doi.org/10.1038/s41598-021-95354-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8338952/
https://www.ncbi.nlm.nih.gov/pubmed/34349202
http://dx.doi.org/10.1038/s41598-021-95354-3

Ejemplares similares